Press Releases

Press Releases

Date Title & Summary Additional Formats
11/27/18
Cidara Therapeutics to Present New Data at ASH 2018 Highlighting Potential of Rezafungin to Prevent Invasive Fungal Infections in Bone Marrow Transplant Patients
SAN DIEGO --(BUSINESS WIRE)--Nov. 27, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting the potential of rezafungin to prevent invasive fungal
11/12/18
Cidara Therapeutics Named a San Diego Metro Area Top Workplace for Second Consecutive Year
Employee feedback places Cidara among top 15 small companies in the area SAN DIEGO --(BUSINESS WIRE)--Nov. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace
11/08/18
Cidara Provides Corporate Update and Reports Third Quarter 2018 Financial Results
SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2018 and provided an update on its corporate
10/24/18
Cidara Therapeutics to Present New Data Highlighting Its Cloudbreak Immunotherapy Platform at the 2018 World Antimicrobial Resistance Congress
SAN DIEGO --(BUSINESS WIRE)--Oct. 24, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new
10/15/18
Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference
SAN DIEGO --(BUSINESS WIRE)--Oct. 15, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in
10/04/18
Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018
STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara’s novel once-weekly
09/27/18
Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections
SAN DIEGO --(BUSINESS WIRE)--Sep. 27, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and
09/25/18
FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program
Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation SAN DIEGO --(BUSINESS WIRE)--Sep. 25, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
09/24/18
Cidara Therapeutics to Present at Two Upcoming Investor Conferences
SAN DIEGO , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at two
09/12/18
Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors
Former Head of Global Government Affairs and Policy at Gilead Sciences led wide-ranging collaborations with leading academic institutions and non-profit groups SAN DIEGO --(BUSINESS WIRE)--Sep. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel